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Genotyping Microarray for CSNB-Associated Genes
Abstract
PURPOSE. Congenital stationary night blindness (CSNB) is a clinically and genetically heterogeneous
retinal disease. Although electroretinographic (ERG) measurements can discriminate clinical subgroups,
the identification of the underlying genetic defects has been complicated for CSNB because ofgenetic
heterogeneity, the uncertainty about the mode of inheritance, and time-consuming and costly mutation
scanning and direct sequencing approaches. METHODS. To overcome these challenges and to generate
a time- and cost-efficient mutation screening tool, the authors developed a CSNB genotyping microarray
with arrayed primer extension (APEX) technology. To cover as many mutations as possible, a
comprehensive literature search was performed, and DNA samples from a cohort of patients with CSNB
were first sequenced directly in known CSNB genes. Subsequently, oligonucleotides were designed
representing 126 sequence variations in RHO, CABP4, CACNA1F, CACNA2D4, GNAT1,GRM6,
NYX, PDE6B, and SAG and spotted on the chip. RESULTS. Direct sequencing of genes known to be
associated with CSNB in the study cohort revealed 21 mutations (12 novel and 9 previously reported).
The resultant microarray containing oligonucleotides, which allow to detect 126 known and novel
mutations, was 100% effective in determining the expected sequence changes in all known samples
assessed. In addition, investigation of 34 patients with CSNB who were previously not genotyped
revealed sequence variants in 18%, of which 15% are thought to be disease-causing mutations.
CONCLUSIONS. This relatively inexpensive first-pass genetic testing device for patients with a
diagnosis of CSNB will improve molecular diagnostics and genetic counseling of patients and their
families and gives the opportunity to analyze whether, for example, more progressive disorders such as
cone or cone-rod dystrophies underlie the same gene defects.
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PURPOSE. Congenital stationary night blindness (CSNB) is a
clinically and genetically heterogeneous retinal disease. Al-
though electroretinographic (ERG) measurements can discrim-
inate clinical subgroups, the identification of the underlying
genetic defects has been complicated for CSNB because of
genetic heterogeneity, the uncertainty about the mode of in-
heritance, and time-consuming and costly mutation scanning
and direct sequencing approaches.
METHODS. To overcome these challenges and to generate a
time- and cost-efficient mutation screening tool, the authors
developed a CSNB genotyping microarray with arrayed primer
extension (APEX) technology. To cover as many mutations as
possible, a comprehensive literature search was performed,
and DNA samples from a cohort of patients with CSNB were
first sequenced directly in known CSNB genes. Subsequently,
oligonucleotides were designed representing 126 sequence
variations in RHO, CABP4, CACNA1F, CACNA2D4, GNAT1,
GRM6, NYX, PDE6B, and SAG and spotted on the chip.
RESULTS. Direct sequencing of genes known to be associated
with CSNB in the study cohort revealed 21 mutations (12 novel
and 9 previously reported). The resultant microarray contain-
ing oligonucleotides, which allow to detect 126 known and
novel mutations, was 100% effective in determining the ex-
pected sequence changes in all known samples assessed. In
addition, investigation of 34 patients with CSNB who were
previously not genotyped revealed sequence variants in 18%,
of which 15% are thought to be disease-causing mutations.
CONCLUSIONS. This relatively inexpensive first-pass genetic test-
ing device for patients with a diagnosis of CSNB will improve
molecular diagnostics and genetic counseling of patients and
their families and gives the opportunity to analyze whether, for
example, more progressive disorders such as cone or cone–rod
dystrophies underlie the same gene defects. (Invest Ophthal-
mol Vis Sci. 2009;50:5919–5926) DOI:10.1167/iovs.09-3548
Congenital stationary night blindness (CSNB) is a clinicallyand genetically heterogeneous retinal disease. It can be
associated with deficiency of vision under dim light conditions,
nystagmus, refractive error, or retinal changes. Electroretinog-
raphy is helpful in confirming and subclassifying the disorder.
The disease can also be classified with respect to the gene
defect. Mutations in genes involved in the phototransduction
cascade (GNAT1, PDE6B, RHO, RHOK, and SAG) are among
those that can lead to autosomal dominant CSNB. Although the
phenotype of patients with mutations in GNAT1, PDE6B, or
RHO may vary, the disease course seems to be stationary with
primarily scotopic vision affected.1 Mutations in RHOK and
SAG lead to Oguchi disease,2 which is a rare, autosomal reces-
sive, nonprogressive congenital night blindness. It is character-
ized by a diffuse grayish white discoloration of the fundus that
disappears after a long period of dark adaptation (Mizuo phe-
nomenon).3 Reduced rod function will improve after an ex-
tended period of dark adaptation. Mutations in genes involved
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downstream of the phototransduction cascade can lead to
either a complete or incomplete type of CSNB. Both types are
characterized by an absent or severely reduced b-wave in the
mixed ERG response, revealing a so-called electronegative
ERG. The incomplete phenotype is characterized by a defect in
the ON/OFF pathway and has been associated with mutations
in genes (CACNA1F, CABP4, and CACNA2D4) that are essen-
tial for glutamate release from photoreceptors to the adjacent
bipolar cells. Although mutations in CACNA1F are associated
with X-linked recessive inheritance, mutations in CABP4 and
CACNA2D4 are associated with an autosomal recessive trait.
The complete CSNB phenotype is mainly associated with a
defect in the ON pathway. It has been associated with a gene
important for glutamate uptake (GRM6) and a gene of un-
known function (NYX). Mutations in GRM6 lead to autosomal
recessive CSNB. Alterations in NYX lead to X-linked recessive
CSNB (reviewed in Zeitz4). Although the disease course of
CSNB has been described as nonprogressive, it may be pro-
gressive, at least in some patients carrying mutations in
CACNA1F,5–7 CABP4,8 or CACNA2D4.9 In summary, to date,
10 different genes have been associated with CSNB, with the
majority (80%) of mutations identified in CACNA1F and NYX.4
It is difficult in some cases to define the appropriate gene
for mutation screening, because clinical data do not clearly
identify the subtype or the mode of inheritance is not obvious
(e.g., sporadic cases). In addition, disease-associated patho-
genic variants identified in the 10 known genes so far have
shown to be substantially heterogeneous with regard to clini-
cal phenotypes. Currently, more than 100 different disease-
associated variants have been identified in known CSNB genes.
To generate a time- and cost-efficient mutation-screening
tool, we sought to develop a CSNB genotyping microarray. To
cover as many mutations as possible on such a diagnostic tool,
the DNA from our cohort of patients with CSNB was first
sequenced in known CSNB-associated genes. These samples
and those from previously characterized patients were also
used to validate the microarray. The microarray was further
tested on DNA samples of patients with CSNB of unknown
genotype.
METHODS
Patients
The patients with CSNB involved in the study had the disease diag-
nosed in different centers in Europe and Canada (The Netherlands:
Utrecht, Nijmegen, and Zeist; Belgium: Ghent; France: Paris and Mont-
pellier; Germany: Freiburg, Erlangen, Giessen, Regensburg and Tu¨-
bingen; Switzerland: Bern, Lausanne, and Basel; and Canada: Toronto).
Research procedures were conducted in accordance with institutional
guidelines and the Declaration of Helsinki. Before genetic testing,
informed consent was obtained at each site from all patients, for
diagnostic and/or research purposes, as appropriate.
Selection of Oligonucleotide Sequences to be
Spotted on the Microarray
For the arrayed primer extension (APEX) microarray (Asper Biotech
Ltd., Tartu, Estonia), 126 sequence variants were selected from multi-
ple sources, including recent mutations identified in our laboratory and
mutations or putative polymorphisms found in a comprehensive liter-
ature and database search.4 DNA was extracted by standard methods
(detailed information is available on request) and mutation analyses of
CABP4, CACNA1F, CACNA2D4, GRM6, NYX, and RHO were per-
formed as described recently.8–11 Mutation analyses for GNAT1 and
PDE6B were performed by PCR-amplification of the 8 coding exons of
GNAT1 in 5 amplicons and the 22 coding exons of PDE6B in 20
fragments, by applying a polymerase enzyme (HotFire, Tartu, Estonia)
and subsequently using direct sequencing (detailed conditions on
request). Since none of our patients showed the typical fundus asso-
ciated with Oguchi’s disease, no sequence analysis of SAG and RHOK
was performed.
Design of the CSNB Microarray: APEX Technology
We used APEX technology for designing a new microarray which is
able to detect the 126 different CSNB-related variants. The assay is
based on single-primer nucleotide extension,12 and subsequently con-
verted to an array format.13 Detailed description of the methodology is
available (Asper Biotech, Ltd., http://www.asperbio.com) and provided in
the Supplementary Data, http://www.iovs.org/cgi/content/full/50/12/
5919/DC1. In brief, 5-modified (6-amino linker), sequence-specific
oligonucleotides are arrayed on a glass slide. These oligonucleotides
are designed with their 3-end immediately adjacent to the variable
site. PCR-prepared and -fragmented target nucleic acids are annealed to
oligonucleotides on the slide, followed by sequence-specific extension
of the 3-ends of primers with fluorescence-labeled nucleotide ana-
logues (ddNTPs) by DNA polymerase.14 Reading of the incorporated
fluorescence identifies the target sequence. APEX and PCR oligonucle-
otide primers were designed according to the wild-type gene se-
quences (ref. numbers.: CABP4, NM_145200; CACNA1F, AJ006216;
CACNA2D4, NM_172364; GNAT1, NM_144499; GRM6, NM_000843;
NYX, AJ278865; PDE6B, NM_000283; RHO, NM_000539; and SAG,
NM_000541; provided in the public domain by the National Center for
Biotechnology Information [NCBI], Bethesda, MD at http://www.
snpper.chip.org, http://www.ncbi.nlm.nih.gov) for both sense and
antisense strands.
Databases Used to Predict the Pathogenic
Character of a Sequence Alteration
The following databases were used to evaluate the potential pathoge-
nicity of sequence alterations: NCBI: http://www.ncbi.nlm.nih.gov/
sites/entrez?dbsnp&cmdsearch&term/; Human Genome Browser:
http://genome.brc.mcw.edu/cgi-bin/hgBlat/; GenCards: http://www.
genecards.org/; PolyPhen (Polymorphism Phenotyping, http://genetics.
bwh.harvard.edu/pph/, based on the information of sequence ho-
mologies and mapping of the affected amino acid to known 3-D
protein structures15,16; and SIFT (Sorting Intolerant From Tolerant,
http://blocks.fhcrc.org/sift/SIFT.html, Fred Hutchinson Cancer Center,
Seattle, WA), which uses sequence homologies to predict whether an
amino acid will affect protein function.17 CSNB mutations are anno-
tated according to the recommendation of the Human Genome Varia-
tion Society with nucleotide position1 corresponding to the A of the
translation initiation codon ATG in the cDNA nomenclature (http://
www.hgvs.org/mutnomen).
RESULTS
Design of the CSNB Genotyping Microarray
To date, more than 100 CSNB-associated mutations in 10 dif-
ferent genes have been identified (see review by Zeitz4). To
cover as many mutations as possible on a genotyping microar-
ray, we first sequenced the samples from our CSNB DNA
cohort in known CSNB genes. We identified 21 different mu-
tations (Supplementary Table S1; both Supplementary Tables
are online at http://www.iovs.org/cgi/content/full/50/12/5919/
DC1). These included two recently described mutations: a
RHO mutation that co-segregates with an autosomal dominant
CSNB-phenotype in a large Swiss family and an NYX deletion
frequently occurring in Flemish patients with CSNB (Supple-
mentary Table S1). In addition, seven known mutations in the
two X-linked genes were identified: three in NYX and four in
CACNA1F (Supplementary Table S1). To our knowledge, the
remaining 12 mutations have not been described. Six of those
were found in NYX and six in CACNA1F (Table 1, Supplemen-
tary Table S1). From those patients in whom ERG examinations
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discriminated the complete and incomplete form of CSNB,
mutations in NYX were found to be associated in patients with
the complete form, whereas mutations in CACNA1F were
associated with incomplete CSNB. Some patients with
CACNA1F mutations showed a slightly more progressive phe-
notype. Segregation of the respective mutation with the phe-
notype was shown for those patients for whom other family
members were available for analysis (e.g., patient 715.01; Fig.
1). In addition, control DNA samples were investigated for
novel mutations of uncertain pathogenicity (Supplementary
Table S1).
These mutations, a large fraction of previously described
mutations, and sequence variants with unknown pathogenic
character were used to generate the genotyping microarray.
Specific deletions or mutations that did not reveal a specific
signal during the validation procedure were omitted. This
method resulted in a genotyping microarray containing 126
sequence variants of nine different genes implicated in CSNB:
2 CABP4, 63 CACNA1F, 2 CACNA2D, 1 GNAT1, 12 GRM6, 37
NYX, 1 PDE6B, 4 RHO, and 4 SAG mutations. To facilitate the
TABLE 1. Summary of Novel CSNB Causing Mutations in NYX
and CACNAIF
Gene/Exon
Nucleotide
Change Effect
NYX
3 c.65GA p.Trp22Stop
3 c.143GA p.Cys48Tyr
3 c.187GT p.Glu63Stop
3 c.518GC p.Arg173Pro
3 c.607CT p.Gln203Stop
3 c.1370_1387del18 p.Gln457_Ala463delinsPro
CACNAIF
7 c.935delA p.Asp312ThrfsX10
23 c.2797GT p.Asp933Tyr
28 c.3400GA p.Glu1134Lys
29 c.3471_3472delGC p.Gln1157HisX25
38 c.4424TC p.Leu1475Pro
38 c.4466CG p.Pro1481A1a
Direct sequencing of DNA from patients revealed six novel NYX
and six novel CACNA1F mutations.
FIGURE 1. The electropherogram
shows the novel dinucleotide dele-
tion c.3471_3472delGC in exon 29
of CACNA1F in patient 715.01. The
mother (715.02) was heterozygous
for the deletion. The grandfather
(715.03) and the brother (715.04)
were hemizygous for this mutation.
Squares: males; circles: females;
dots: carriers; filled symbols: affect-
ed; open symbols: healthy.
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interpretation of the outcome of such a microarray screening
with CSNB patient samples with unknown genotype, we pro-
vide the original references in this study (Supplementary Table
S2).
Validation of the CSNB Genotyping Microarray
The genotyping CSNB microarray was first validated with
marked oligonucleotides, which served as positive internal
controls. In addition, a negative control (with no DNA) was
used to investigate the nonspecific background signal. To fur-
ther test the capability of the microarray to detect sequence
alterations, we screened 39 DNAs from patients with 37
known variants. All the expected variants were detected with
100% accuracy (Supplementary Table S2).
Screening Results in Previously Untested Patients
with CSNB
To further evaluate the clinical validity of the CSNB array, we
screened 34 additional patients with CSNB with unknown
gene defect. Patients from different clinical centers were in-
cluded in this study. This multicenter recruitment resulted in
variability in the methods used to clinically assess patients
included in the study. The screening, which was confirmed by
direct sequencing, resulted in the detection of six sequence
alterations in CACNA1F, of which five are thought to be disease
causing (Table 2, Supplementary Table S2).
In summary, our screening detected sequence variants in
18% of these patients, of which 15% are thought to be patho-
genic.
Rationale for Six CSNB Patients Screened on the
Microarray Showing a Known CACNA1F Mutation
Patient 27538, had a c.2899CT mutation in CACNA1F, which
is predicted to lead to a premature stop codon at amino acid
position 967 (p.Arg967Stop). His parents are consanguineous,
and autosomal recessive inheritance was suspected. Because of
the mutation identified in CACNA1F the assumed mode of
inheritance was shown to be wrong. He is the only affected
member of the family, and he shows a clear incomplete type of
CSNB (Table 2).
The 12-year-old male patient CIC00196 with a
c.3019GA transition (p.Gly1007Arg) substitution in exon
25 of CACNA1F is a sporadic case. Mutation analysis in his
father and mother did not show the mutation and thus the
c.3019GA transition represents a de novo mutation. Clin-
ical data from this patient were suggestive of the incomplete
type of CSNB (Table 2).
The 18-year old-male patient CIC00748 with a c.3862CT
transition in CACNA1F leading to a nonsense mutation
(p.Arg1288Stop) in exon 33 mentioned having an affected
cousin, indicative of an X-linked mode of inheritance. Again,
clinical observations were suggestive of the incomplete type of
CSNB (Table 2).
Clinical data for patient CH2718, revealing the
c.945_947delCTT (p.Phe316del) in exon 7 in CACNA1F, and
of patient 825.01 with a c.4091TA mutation in CACNA1F
(p.Leu1364His), showed an incomplete type of CSNB (Ta-
ble 2).
Patient D0706932, with the putative splice site mutation,
c.26733GA in intron 21 in CACNA1F represents a simplex
male case showing clinically signs and symptoms of incom-
plete CSNB (Table 2). However, further investigation of this
variant explained in the next paragraph showed that this vari-
ant is probably not disease causing.
In summary, all six patients with a CACNA1F sequence
alteration detected by our microarray showed an incomplete
CSNB phenotype that is in accordance with this gene defect.
Except for the predicted splice site mutation c.26733GA in
intron 21, the identified mutations can be considered to be
disease causing.
Detection of Additional Variants in Patients with
Known Genotype
The microarray screening revealed three additional CACNA1F
variants in patients with known disease-associated sequence
variations. These variants were verified by direct sequencing
TABLE 2. Detection of Known Mutations in Patients with the CSNB Genotype Microarray
Index Phenotype Gene
Exon
Intron
Nucleotide
change Effect Publication Interpretation
CH2718 Incomplete CSNB CACNAIF Exon 7 c.945_947delCTT p.Phe316del 21 Disease causing
D0706932 Incomplete CSNB CACNAIF Intron 21 c.26733GA Splice defect 18 SNP or modifier
27538 Incomplete CSNB CACNAIF Exon 24 c.2899CT p.Arg967Stop 27, 31 Disease causing
C1C00196 Incomplete CSNB CACNAIF Exon 25 c.3019GA p.Gly1007Arg 18 Disease causing
C1C00748 Incomplete CSNB CACNAIF Exon 33 c.3862CT p.Arg1288Stop 21, 33 Disease causing
825.01 Incomplete CSNB CACNAIF Exon 35 c.4091TA p.Leu1364His 27 Disease causing
TABLE 3A. Variants Detected by Screening Patients with Known Genotype or Unclear Pathogenic Character
Gene
Exon
Intron
Nucleotide
Change Effect Publication Index Interpretation
CACNAIF Exon 13 c.1523GA p.Arg508Gln 27 5854, 2422 SNP or modifier
CACNAIF Exon 16 c.2204AC p.Asn735Thr 8 13276 SNP or modifier, unclear
CACNAIF Intron 21 c.26733GA Splice defect 18 MT, 446.1, DO706932 SNP or modifier
CACNAIF Intron 24 c.2938IGA Splice defect 21 1344.01 Female SNP or modifier, unclear
GRM6 Exon 3 c.727GT p.Val243Phe This study, 23 13154, 7330 SNP or modifier
GRM6 Exon 3 c.824GA p.Gly275Asp This study 8798 Unclear
GRM6 Exon 8 c.2090AT, p.Gln697Lcu This study 7699 Unclear
CACNA2D4 Exon 25 c.2452CT p.Arg818Cys This study Not tested Unlcear
Based on the phenotype, functional analysis, or co-segregation studies, these variants are interpreted as nonpathogenic or of unclear
pathogenicity.
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(Supplementary Table S2 and Table 3A) and described in more
detail in the following sections.
Predicted Splice Site Mutation: c.26733G>A. Patient
MT (a woman) showed a homozygous c.1214TC transition
(p.Ile405Thr) in GRM6, and patient 446.1 revealed a
c.518GC transversion (p.Arg173Pro) in NYX (Table 3B). In
addition, both patients carried a known predicted splice site
mutation (c.26733GA)18 in CACNA1F (Table 3A). Clinical
examination including electroretinography of the female pa-
tient MT revealed autosomal recessive complete CSNB.19 Func-
tional analysis of the c.1214TC transition in GRM6 showed
that the phenotype is due to the absence of the receptor on the
cell surface.20 The c.26733GA change in CACNA1F was
heterozygous in MT. These findings indicate that the GRM6
mutation is the disease-causing mutation in this patient and not
the CACNA1F variant (Tables 3A, 3B).
Clinical examination including electroretinography of pa-
tient 446.1 was consistent with complete XlCSNB. Mutation
analysis in NYX identified a novel hemizygous c.518GC trans-
version leading to a p.Arg173Pro substitution, which co-segre-
gates with the phenotype (the affected brother and grandfa-
ther were hemizygous, whereas the mother was
heterozygous). The association of the complete form of X-
linked recessive CSNB with NYX mutations and co-segregation
of the mutation in the family supports the hypothesis that the
NYX mutation is indeed the disease-causing mutation and not
the CACNA1F splice site mutation (Tables 3A, 3B).
The predicted splice site mutation c.26733GA in
CACNA1F was first described in two patients from two inde-
pendent families (T10, T26).18 T10 was a simplex case and
thus co-segregation analysis was not performed, whereas co-
segregation was observed in the family of T26 (the affected
brother was also hemizygous and the mother was a carrier).
Because of co-segregation and the site of the variant in the
consensus sequence of the splice donor site, the
c.26733GA was assumed to be pathogenic. However, now
different databases (NCBI, Human Genome Browser) indicate
that this substitution represents an SNP (rs41312124), al-
though the frequency in different populations has not been
defined. Taking into account the complete phenotype of our
patients, as well as results of functional20 and co-segregation
analyses, we suggest that the c.26733GA in CACNA1F re-
flects either a rare SNP or a variant modifying the phenotype of
the patients (Table 3A).
Predicted Splice Site Mutation: c.29381G>A. Another
known CACNA1F predicted splice site mutation (c.2938
1GA)21 was heterozygous in case 1344.01. This woman was
clinically diagnosed with incomplete CSNB. Co-segregation
analysis revealed that her unaffected sister was also heterozy-
gous for the variation, her unaffected father was hemizygous
for the variation, and her mother had two wild-type alleles (Fig.
2). These findings indicate that this sequence alteration did not
co-segregate with the phenotype and thus, at least in this
family, is not disease causing (Table 3A). Despite the fact that
this sequence variant seems not to be disease causing the site
is highly conserved and predicted to influence splicing. Splic-
ing assays to be performed in the future will show the conse-
quences of this sequence variant.
c.1523G>A Transition Leading to a p.Arg508Gln. Two
patients, 5854 and 2422, showed a c.1523GA transition caus-
ing a p.Arg508Gln substitution in CACNA1F (Table 3A), in
addition to the already identified p.Asn216Ser (patient 5854)
and p.Leu347Pro exchanges (patient 2422) in NYX, respec-
tively (Table 3B). Re-evaluation of the clinical records of pa-
tient 5854 revealed no details about the CSNB phenotype. The
mutation p.Asn216Ser in NYX has been described to be disease
causing in two independent studies (three families).22,23 In one
of these studies co-segregation was shown in two affected
family members.22 Furthermore, the amino acid asparagine is
highly conserved in a leucine-rich repeat.23 These findings
strongly argue for the fact that this sequence variant in NYX is
indeed the disease-causing mutation (Table 3B).
Patient 2422 is a member of the large Dutch CSNB family
that was used to link CSNB to DXS228, MAOB, and NDP.24
Patients in this family showed clinical symptoms of night blind-
ness, but it is also unclear whether they are affected by the
incomplete or complete type of CSNB. Later, this linkage in-
terval was refined to DXS993 and DXS228. Subsequently, the
NYX gene was identified in this region and shown to carry a
mutation in this family (c.1040TC; p.Leu347Pro) and in other
patients.22,25,26 CACNA1F, in contrast was mapped centro-
meric to DXS2722 and DXS255. With respect to the haplo-
types24 of patient 2422, we suspect that all affected family
members but also one unaffected male (III-524) carry the
p.Arg508Gln substitution in CACNA1F in addition to the NYX
mutation. These findings suggest that, at least for this family
the NYX mutation and not the amino acid substitution in
CACNA1F is indeed disease causing. We cannot exclude the
possibility that the CACNA1F sequence alteration modifies the
phenotype (Tables 3A, 3B).
TABLE 3B. Disease-Associated Genotypes of Patients with Second Variant Listed in Table 3A
Index Phenotype Gene
Exon
Intron
Nucleotide
Change Effect Publication Interpretation
5854 CSNB NYX Exon 3 c.647AG p.Asn216Ser This study, 22, 23 Disease causing
2422 CSNB NYX Exon 3 c.1040TC p.Leu347Pro 26 Disease causing
MT Complete arCSNB GRM6 Exon 6 c.1214TC p.Ile405Thr 20 Disease causing
446.01 Complete XICSNB NYX Exon 3 c.518GC p.Arg173Pro This study Disease causing
13276 Incomplete arCSNB CABP4 Exon 2 c.370CT p.Argl24Cys 7 Disease causing
Exon 6 c.800_801delAG p.Glu267ValfsX92
7330 CSNB NYX Exon 3 c.607CT p.Gln203Stop This study Disease causing
Based on phenotype, functional analysis, or co-segregation studies, these mutations are interpreted as disease causing.
FIGURE 2. Segregation analysis of a heterozygous splice site mutation
(c.29381GA). The index patient (arrow) as well as the unaffected
sister was heterozygous for the variation. The father was hemizygous
for the variation, and the mother had two unaffected alleles.
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The c.1523GA transition leading to a p.Arg508Gln in
CACNA1F itself was first described by Strom et al.27 in two
patients from two different families (03 and 06) (Table 3A). It
was excluded in 120 control chromosomes analyzed by SSCP.
The index patient of family 06 had a second substitution in
CACNA1F (p.Leu849Pro) that was suggested to be non–disease
causing as it “affected a non-conserved leucine.” Hoda et al.28
investigated the functional effect of p.Arg508Gln. They found
no changes in the gating properties of the mutant channel
subunit after heterologous expression in Xenopus laevis oo-
cytes, but identified a temperature-dependent altered expres-
sion density of the Cav1.4 protein encoded by CACNA1F. It
was thus theorized that the amount of expressed protein is
critical for the correct function of the channel.28 Different
databases are available for use in investigating whether an
identified variation is an SNP, based on allele frequency and
evolutionary conservation (NCBI, UCSC Human Genome
Browser and GeneCards). According to several databases, the
sequence variation c.1523GA (p.Arg508Gln) represents an
SNP (rs34162630). Moreover, 294 samples have been investi-
gated in populations from North America, Europe, East Asia,
and West Africa and the A was found at a frequency of 0.25
(04.11.2008). Together, these findings indicate that the
c.1532GA transition in CACNA1F is either a polymorphism or
a sequence alteration modifying the phenotype (Table 3A).
Putative Polymorphisms and/or Disease-
Modifying Sequence Variations on the
CSNB Microarray
In addition to the putative polymorphisms mentioned herein,
other sequence variants, probably also representing SNPs or
modifiers, can be detected with the CSNB genotyping microar-
ray. A CACNA1F mutation c.2204AC (p.Asn735Thr) in exon
16 was has been identified in a patient showing compound
heterozygous mutations in the CABP4 gene. Since his unaf-
fected brother showed this substitution also, the sequence
variant was classified as a rare polymorphism or modifier8
(Tables 3A, B).
Furthermore, three different GRM6 sequence variants were
detected by applying the CSNB microarray (Table 3A): A het-
erozygous c.727GT transversion (p.Val243Phe) in exon 3
was originally detected by direct sequencing of GRM6 in a
patient with CSNB, in whom the ERG data did not discriminate
between the complete and incomplete form (patient 13154,
Tu¨bingen, Germany; CZ, EZ, BW, SK, WB, unpublished data,
2008). Because of the lack of DNA samples of family members,
co-segregation could not be performed. A second mutation was
not identified. We also detected this variant in another patient
from Tu¨bingen (7330) showing a nonsense mutation in NYX
(p.Gln203Stop). The database GeneCards annotates this GRM6
variant as a rare SNP (rs17078894). An investigation of 172 Eu-
ropeans revealed an allele frequency of G: 0.99, T: 0.01 (No-
vember 4, 2008). Two of 178 control alleles analyzed by Dryja
et al.29 showed the same variant, suggesting that the GRM6
variant is not disease causing. In patient 8798, a previously
unreported c.824GA nucleotide exchange (p.Gly275Asp)
was identified in exon 3 of GRM6. Direct sequencing of the
coding exons and flanking intronic regions revealed no second
mutation, and thus it is not clear whether the c.824GA
exchange is pathogenic. A second mutation may represent a
deletion of one or more exons, which would not be detected
by direct sequencing. The c.824GA nucleotide exchange was
neither published nor predicted as an SNP in the available
databases. Family members were not available for co-segrega-
tion analyses. Two bioinformatic algorithms, Polyphen and
SIFT, were applied to predict the pathogenic character of this
substitution: Polyphen classified this variant as probably dam-
aging, whereas in SIFT, it was considered to be benign. A
previously unreported third heterozygous GRM6 sequence
variant was found in exon 8 (c.2090AT, p.Gln697Leu) in a
female patient (7699). Again, due to the absence of a second
mutation, the pathogenic character of the c.2090AT substi-
tution is not clear. It was neither published nor predicted as an
SNP in the databases available and listed herein. Polyphen and
SIFT predicted this variant as probably damaging. However,
because of the absence of a second mutation, it is not clear
whether this substitution in GRM6 is indeed disease causing.
Similarly, when we screened CACNA2D4 for sequence alter-
ations in our CSNB cohort, we detected a heterozygous
c.2452CT transition (p.Arg818Cys) in exon 25 in a patient
with incomplete CSNB. A second mutation was not detected,
and thus the pathogenic character remains to be unresolved. It
was neither published nor predicted as an SNP in available
databases. Polyphen and SIFT predicted this variant as proba-
bly damaging (Table 3A). Functional studies are needed to
determine whether these sequence variations are pathogenic.
Summary of CSNB Microarray
In total of 126 sequence variants can be detected by the CSNB
microarray. Based on the literature and our own validation of
some cases, 118 of those are disease causing, whereas 8 of
them are of uncertain pathogenic character, representing SNPs
or modifiers (Table 3B, Supplementary Table S2). The microar-
ray was 100% effective in detecting known variants and re-
vealed a sequence variant in 18%, of which 15% are thought to
be disease causing in DNA samples with previously unknown
genotype.
DISCUSSION
In this study we established a mutation detection tool for
CSNB, which overcomes costly, low-sensitivity, and time-con-
suming prescreening methods such as SSCP and DHPLC. Al-
though direct sequencing is the gold standard for genetic
testing, genetic heterogeneity and large genes containing more
than 30 exons remain labor intensive to investigate. The ad-
vantage of a CSNB microarray is that this method neither
depends on large family pedigrees with more than one patient
affected nor on a precise clinical discrimination of the different
subforms of CSNB (e.g., incomplete versus complete CSNB;
Table 4).
Initially, mutation analysis in our CSNB cohort was per-
formed by direct sequencing to cover as many mutations as
possible on this microarray. By doing so, 21 mutations were
identified, including 2 recently published and 7 that had been
described earlier. These studies indicated that at least 33% of
patients with CSNB carry a known mutation in one of the
known CSNB-associated genes. These findings led to the as-
sumption that a CSNB microarray is a valuable diagnostic tool
for new patients with CSNB. In total of 126 sequence variants
can be detected by the CSNB microarray. Based on the litera-
ture and our own validations 118 of those are disease causing,
whereas 8 of them are of uncertain pathogenic character,
representing SNPs or modifiers. The microarray was 100%
effective in detecting known variants, and 37 known variations
in 39 DNA samples were reliably detected from both strands.
By applying DNA samples from a CSNB cohort with unknown
gene defect, the chip revealed a sequence variant in 18%, of
which 15% are thought to be pathogenic. The detection rate
may change in the future, when more laboratories are aware of
such an array and will analyze their CSNB cases with this
relatively inexpensive screening method. At this time our co-
hort of patients with CSNB with unknown gene defect was
small (n  34). The remaining mutations not detectable by the
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chip may be identified by direct sequencing of known CSNB
genes or in novel genes underlying this disorder. These data
will be then used to update the chip and will result in a higher
detection rate in the future.
Nevertheless, these initial studies already suggest that the
CSNB microarray is an efficient first-pass screening to detect
known variants. It is especially useful for simplex cases, in
patients in whom the mode of inheritance is unclear and in
whom the ophthalmic examinations do not discriminate be-
tween the incomplete and the complete forms of CSNB. It can
also be used to exclude CSNB cases of known mutations to
furthermore use these samples to identify novel genes under-
lying CSNB by candidate gene approaches and in larger families
by linkage analysis. Certainly, one must be aware that novel
mutations in the known genes are missed by this strategy
(Table 4).
Of note, our preliminary screening of CSNB patients with
unknown gene defects revealed six CACNA1F variants (five
pathogenic and one probable polymorphism or modifier).
CACNA1F consists of 48 coding exons, and thus direct se-
quencing, although it is the gold standard, is still time consum-
ing and costly compared with chip analysis. Therefore, we
suggest that the chip is particularly useful for patients with the
incomplete form of CSNB and in particular for patients with
X-linked inheritance. Taken into account that the autosomal
recessive genes CABP4, CACNA2D4, and GRM6 have been
only recently associated with CSNB, only a few mutations have
been discovered in these genes. Thus, in the near future com-
prehensive analysis of these genes in families with an autoso-
mal recessive inheritance may be more successful in identify-
ing additional disease-causing mutations. The corresponding
oligonucleotides of the newly identified mutations will then be
added on the array and will make this tool also more attractive
for recessive forms.
Furthermore, the CSNB microarray may also be used as a
prescreening method for patients with more progressive reti-
nal disorders including cone- or cone-rod dystrophies. Muta-
tions in CACNA1F, CABP4, as well as CACNA2D4 have been
identified in patients initially diagnosed with nonprogressive
CSNB. However, in some cases the phenotype turned out to be
more progressive than originally believed. The diagnosis is
often based on a first examination by ERG, revealing the typical
electronegative ERG that is associated with CSNB.30 Several
cases with CACNA1F mutations have been reported in which
either the same or different mutations lead to different pheno-
typic manifestations varying from classical incomplete CSNB to
retinal and optic atrophy with a clinical progressive course of
visual dysfunction and to X-linked cone–rod dystrophy.4–7,31
Similar phenotypic variations have been reported in pa-
tients carrying CABP4 mutations. Two male patients from the
same family with the same homozygous frameshift mutation
developed either incomplete CSNB or a more progressive form
associated with a decrease in visual acuity and photophobia,
respectively.8 Of interest, just recently a novel homozygous
mutation in CABP4 (p.Arg216Stop) was described leading to a
congenital cone–rod synaptic disorder. The Dutch sib pair
carrying this novel mutation showed reduced visual acuity,
photophobia, and abnormal color vision, without symptoms of
night blindness. Clinical presentations and ERG measurements
displayed a predominant cone dysfunction.32
Mutations in CACNA2D4 have been identified in a patient
with the full-field ERG results suggestive of incomplete CSNB.
However, the patient showed a mild form of cone dystrophy
with a progressive decrease in visual acuity.9 These studies
indicate that the initial clinical diagnosis, especially for incom-
plete CSNB, must be validated over a certain time period. In
some cases, the disease course turns out to be progressive
rather than stationary or can even result in another severe
retinal disease.
Thus, the CSNB microarray can also be considered for
patients showing a more progressive form than the classic
incomplete CSNB. It would also be interesting to investigate
whether CACNA1F plays an important role in patients showing
cone or cone–rod dystrophies.
As in our case, screening patients with known disease-
associated sequence variations on such a microarray can also
reveal unexpected findings. The chip outcome should always
be compared to the respective references presented herein. In
addition, for diagnostic purposes, it is mandatory to validate
the outcome by direct sequencing and to perform co-segrega-
tion analysis if family members are available and, for autosomal
recessive conditions, to screen the whole gene in case of
identification of only one disease allele by the chip.
In conclusion, the microarray presented herein offers a
prescreening tool for CSNB diagnostics. It is not only a cost-
efficient method of screening patients with the different forms
of CSNB but can also be used to test the hypothesis that
CACNA1F plays an important role in more progressive retinal
disorders like cone- or cone–rod dystrophies. Furthermore, as
new mutations are identified, updated versions of the microar-
ray will be generated in regular time intervals. The detailed
information concerning the origin and clinical context of the
TABLE 4. Advantages and Disadvantages of the CSNB Microarray
Advantage Disadvantage
Robust Detects only known variants
Can be updated regularly with new mutations Detection rate at the moment only 15%–18%, new mutations can
be added only after direct sequencing of CSNB genes
Validated with patients from different ethnic backgrounds Number of patients at the moment low (39 DNA samples with
known mutation, 34 with unknown genotype in which 6
showed a mutation on microarray screening)
Inexpensive If no mutation is detected CSNB genes need to be sequenced
directly
Simplex cases can be used To confirm pathogenic character of mutation larger family still
advantageous for cosegregation studies
Mutation detection does not depend on precise clinical
discrimination
Exclusion of CSNB mutation to use DNA for linkage or
candidate gene approaches to identify new genes
Prescreening method for diagnostics Sequence validation required
Each sequence variant on the microarray can be followed up by
the given reference
Needs careful interpretation and validation of the original reference
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mutations described herein will help to better interpret the
results of chip screening.
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